Bio-Techne Q1 GAAP EPS $0.31 (down 44% YoY); CEO Kelderman appointed

its financial results for the first quarter ended September 30, 2023. ​ First Quarter FY2024 Highlights ​ ● First quarter organic revenue increased by 2% (3% reported) to $276.9 million. ​ ● GAAP earnings per share 1) (EPS) was $0.31 versus $0.55 one year ago. Delivered adjusted EPS 1) of $0.41 compared to $0.45 one year ago. ​ ● Our ExoDx prostate test and GMP

Proposal No. 5 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. 40 ​ For Against Abstain ​ 140,734,676 5,247,721 35,466

Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: ​ ​ For Against Abstain Broker Non-Vote Robert V. Baumgartner 100,149,013 41,734,415 66,390 4,068,045 Julie L. Bushman 132,251,087 9,638,369 60,362 4,068,045 John L. Higgins 116,991,416 24,891,094 67,308 4,068,045 Joseph D. Keegan 134,547,666 7,343,701 58,451 4,068,045 Charles R. Kummeth 139,037,662 2,847,756 64,400 4,068,045 Roeland Nusse 136,502,096 5,384,164 63,558 4,068,045 Alpna Seth 134,785,952 7,102,985 60,881 4,068,045 Randolph C. Steer 116,461,357 25,398,613 89,848 4,068,045 Rupert Vessey 134,555,098 7,335,534 59,186 4,068,045 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.

Proposal No. 3 – The shareholders voted against a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: 9, For Against Abstain Broker Non-Vote 49,894,295 91,277,734 777,789 4,068,045

Proposal No. 4 – The shareholders approved the frequency of future advisory votes on executive compensation to occur every year. 39 ​ 1 Year 2 Years 3 Years Abstain 139,718,743 141,528 939,375 1,150,172

Proposal No. 1 – The shareholders voted to set the number of directors at nine: ​ ​ For Against Abstain ​ 141,242,833 672,919 34,066